Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00008281
- Locations
- 🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States
🇺🇸Medical Oncology Internal Medicine, Los Angeles, California, United States
Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00017459
- Locations
- 🇺🇸
University of Florida Health Science Center - Jacksonville, Jacksonville, Florida, United States
🇺🇸Los Angeles County Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸John Wayne Cancer Institute, Santa Monica, California, United States
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00077805
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey
EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4726
- Registration Number
- NCT00077753
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom
Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00077818
SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis
- Conditions
- First Posted Date
- 2003-10-20
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1215
- Registration Number
- NCT00071279
- Locations
- 🇺🇸
Cardinal Bernardin Cancer Center, Maywood, Illinois, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇨🇦University of Alberta, Edmonton, Alberta, Canada
Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)
- Conditions
- First Posted Date
- 2003-10-09
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4673
- Registration Number
- NCT00070655
- Locations
- 🇨🇦
Saskatoon Medical Specialists, Saskatoon, Saskatchewan, Canada
🇨🇦Health Care Corporation of St. John's Health Sciences Centre, St. John's, Newfoundland and Labrador, Canada
🇨🇦Yorkton Regional Health Centre, Yorkton, Saskatchewan, Canada
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
- First Posted Date
- 2003-10-06
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 12537
- Registration Number
- NCT00069784
- Locations
- 🇻🇪
Makati City, Caracas, Venezuela
🇬🇧Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom
🇷🇺Sanofi-Aventis Aministrative Office, Moscow, Russian Federation
A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following Prostatectomy
- Conditions
- First Posted Date
- 2003-10-06
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 83
- Registration Number
- NCT00069888
- Locations
- 🇺🇸
Sanofi-Aventis US, Bridgewater, New Jersey, United States
Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)
- Conditions
- First Posted Date
- 2003-08-13
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1452
- Registration Number
- NCT00067093
- Locations
- 🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States
🇺🇸MIMA Century Research Associates, Melbourne, Florida, United States
🇺🇸Jackson Cardio-Vascular Clinic, Jacksonville, Florida, United States